NUVB News and Press, Nuvation Bio Inc. Class A From 05/17/21

Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update Ongoing enrollment in Phase 1/2 study of NUV-422 in high-grade gliomas Strong balance sheet with cash, cash equivalents and marketable securities of $824.7million as of March 31, 2021 ...

The latest SPAC from Panacea Acquisition (NUVB), who took preclinical stage oncology company Nuvation Bio public through a reverse merger, will begin trading Wednesday, April 7, after staging $150M IPO in biotechnology sector.Panacea Acquisition Corp II prices its initial ...

Nuvation Bio (NUVB): FY Net loss of $41.7M.Cash and cash equivalents of $29.76MPress Release For further details see: Nuvation Bio reports FY results

Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update Closed business combination with Panacea, yielding new public listing and strong cash position of approximately $830 million Patient enrollment ongoing in Phase 1/2 study of NUV-422 in high-gr...

Nuvation (NUVB) announces that the U.S. FDA has granted Orphan Drug Designation to NUV-422, a cyclin-dependent kinase ((CDK)) 2/4/6 inhibitor, for the treatment of patients with malignant gliomas.Gliomas, which begin in the glial or supportive tissue, represent 75% of malignant primary b...

Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas PR Newswire NEW YORK , March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet...